iPCE120

iPCE120 is a preclinical-stage small molecule chemotherapy candidate developed by Cello Therapeutics. It is part of the company's pipeline of cellular nanoparticle (CNP) therapeutics, which utilize a proprietary platform to coat drug-loaded cores with natural cell membranes (such as those from red blood cells or platelets). This biomimetic approach is designed to enhance the drug's biocompatibility, extend its systemic circulation time, and improve targeted delivery to tumor tissues while evading immune clearance. iPCE120 is specifically categorized as an immune-evasive nanoparticle formulation of a chemotherapy agent, currently undergoing IND-enabling studies for the treatment of solid tumors.